Physician profile
Douglas C Brewer
NPI 1437116613
$3,354.57
in general payments reported to CMS, 2019-2025
26 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $235 · 2021: $519 · 2022: $380 · 2023: $710 · 2024: $560 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.31 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,076.53 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Novo Nordisk INC | $544.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $258.81 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $242.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $184.33 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.49 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $132.37 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.90 | 2021 | |
| Intercept Pharmaceuticals, INC. | $87.95 | 2023 | Ocaliva |
| Abbvie INC. | $75.26 | 2019-2025 | |
| Harmony Biosciences LLC | $69.38 | 2023 | Wakix |
| Janssen Pharmaceuticals, INC | $67.13 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $60.75 | 2019-2022 | |
| Pfizer INC. | $53.92 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $45.11 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $32.91 | 2022 | |
| Recordati_rare_diseases_inc. | $23.49 | 2024 | Signifor Lar, Isturisa |
| Travere Therapeutics, INC. | $21.32 | 2023 | |
| Idorsia Pharmaceuticals US INC | $19.34 | 2023 | Quviviq |
| Janssen Biotech, INC. | $16.12 | 2022 | |
| Exact Sciences Corporation | $15.35 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $15.25 | 2021 | |
| Cashflow Solutions, LLC | $15.04 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Takeda Pharmaceuticals U.S.A., INC. | $12.96 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.33 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.